February 14, 2021
During its Q4 2021 earnings call, Prothena gave an update on its prasinezumab clinical program for Parkinson’s disease. During the clinical overview, Prothena highlighted that prasinezumab specifically targets the C-terminus of alpha-synuclein and is the “first antibody to show significant slowing of motor progression and improvements in imaging biomarkers.” The company stated that preclinical studies had shown that targeting the N-terminus was suboptimal and proposed it as a potential hypothesis on why Biogen’s cinpanemab failed, a point later reiterated during the Q&A.
Prothena remains very encouraged by efficacy signals observed in its Phase 2 PASEDENA Part 1 study. Data from pre-specified exploratory subgroup analysis from the PASEDENA Part 1 study will be presented at the ADPD conference in March. Prothena expects Roche to present results from PASEDENA Part 2 at a future medical conference.
Roche is expected to initiate the Phase 2b study of prasinezumab in Parkinson’s disease in Q2 2021 with details to come in Q2 as well. Prothena will earn $60M clinical milestone payment upon dosing of first patient. Read more